US doctors likely to keep denosumab as second- or third-line therapy for PMO
14 December 2009
Nancy Faigen
Please Login to read the full article.
14 December 2009
Nancy Faigen
The majority of US clinicians surveyed by Decision Resources would use
Amgen's investigational monoclonal antibody Prolia (denosumab), which is given by subcutaneous injection twice yearly, as either a second- or third-line therapy for osteoporosis if the product receives regulatory approval...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amgen & UCB unveil positive AMG 785/CDP7851 PMO data
- Ibandronate set for filing in Japan following positive local trial
- With questions raised on prostate cancer benefit, Amgen's Xgeva may face tough ODAC
- FDA panel calls for clarity on duration of bone drug use, but sets no cutoff
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
